drugset / Trial / NCT00172016

A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates

NCT00172016

Phase 4 Completed 43 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and tolerability of zoledronic acid in preventing skeletal-related events in patients with prostate cancer

Timeline

Start
2004-01
Primary completion
2005-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified

Indications

No indication recorded.